Lyell Immunopharma, Inc. · NASDAQ:LYEL
Lyell Immunopharma — American Society of Hematology (ASH) 2025
21 slides from Lyell Immunopharma's conference presentation, Dec 7, 2025
Slide 1: CD62L Enrichment Achieves Robust Expansion and Memory Phenotype Post-Infusion in LBCL
CD62L Enrichment Achieves Robust Expansion and Memory Phenotype Post-Infusion in Patients with LBCL Treated with Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate Akil Merchant1, Ben Harris2, Lora Zhao2, Sahithi Cheemalamarri2, Shobha Potluri2, Tahir Latif3, Uma
Slide 2: Higher Complete Response Rates and Longer Duration of Responses Needed in LBCL
Higher Complete Response Rates and Longer Duration of Responses Needed in LBCL Enrichment for stem-like CAR T-cells has promise in improving outcomes for patients • Only ~50% of patients with 3L+ LBCL treated with approved CD62L CD19 CAR T-cell therapies (axi-cel, liso-cel) achieve a complete respon
Slide 3: Dual-Targeting CD19/CD20 CAR T-Cells Enriched for Stem-Like Phenotype (CD62L+)
Dual-Targeting CD19/CD20 CAR T-Cells Enriched for Stem-Like Phenotype (CD62L+) Rondecabtagene autoleucel (ronde-cel) designed to achieve high complete response rates and long duration of responses Ronde-cel • Ronde-cel is a true CD19/CD20 "OR" logic-gated CAR ◦ Designed to target either CD19 and CD2
Slide 4: High Overall Response Rate in Patients with 3L+ and 2L LBCL
High Overall Response Rate in Patients with 3L+ and 2L LBCL Presented at the 18th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 2025 Best Overall Response (3L+) N = 25 • Phase 1/2 multi-cohort, multi-center study with aggressive LBCL (CAR naïve), with the 3L+ cohor
Slide 5: Summary of Key Translational Findings
CD62L+ Enrichment of T Cells Achieves Robust Expansion, Memory Phenotype, and Sustained Function After Infusion in Patients with Large B-Cell Lymphoma Summary of Key Translational Findings Ronde-cel drug products have a high proportion of CD62L+ cells with a stronger memory-cell 1 phenotype compared
Slide 6: Summary of Key Translational Findings
CD62L+ Enrichment of T Cells Achieves Robust Expansion, Memory Phenotype, and Sustained Function After Infusion in Patients with Large B-Cell Lymphoma Summary of Key Translational Findings Ronde-cel drug products have a high proportion of CD62L+ cells with a stronger memory-cell 1 phenotype compared
Slide 7: Ronde-Cel Has a High Percentage of CD62L+ Cells in the Final Drug Product
Ronde-Cel Has a High Percentage of CD62L+ Cells in the Final Drug Product CD62L+ enrichment is a simple process that does not increase overall manufacturing time Ronde-cel Manufacturing Product Characteristics • Ronde-cel drug products profiled with flow cytometry (N = 84) Median (Range) % CD3+ of V
Slide 8: CD62L+-Enriched Ronde-Cel Has a Stronger Memory-Cell Phenotype Prior to Infusion
CD62L+-Enriched Ronde-Cel Has a Stronger Memory-Cell Phenotype Compared to Approved CD19 CAR T-Cell Products Prior to Infusion Transcriptional profiling performed using single-cell RNA-seq Assess memory and effector phenotype of CAR+CD8+ cells at both individual genes and geneset (GSVA) level Axi-ce
Slide 9: Ronde-Cel Has a Stronger Memory Phenotype Compared to Approved CD19 CAR T-Cell Products
Ronde-Cel has a Stronger Memory Phenotype Compared to Approved CD19 CAR T-Cell Products Higher relative expression of individual memory-related genes (CD62L, IL7R, LEF1) and memory geneset (group of 53 genes) Individual Memory-Related Genes Memory Geneset CD62L IL7R LEF1 Central Memory Marker Centra
Slide 10: Ronde-Cel Has Less of the Short-Lived Effector Phenotype
Ronde-Cel has Less of the Short-Lived Effector Phenotype Compared to Approved CD19 CAR T-Cell Products Lower relative expression of individual effector-related genes (GZMB, BATF, CD57) and effector geneset (group of 180 genes) Individual Effector-Related Genes Effector Geneset GZMB BATF CD57 Effecto
Slide 11: Summary of Key Translational Findings
CD62L+ Enrichment of T Cells Achieves Robust Expansion, Memory Phenotype, and Sustained Function After Infusion in Patients with Large B-Cell Lymphoma Summary of Key Translational Findings Ronde-cel drug products have a high proportion of CD62L+ cells with a stronger memory-cell 1 phenotype compared
Slide 12: Up to 3-Fold Higher Cell Expansion with Ronde-Cel After Infusion
Up to 3-Fold Higher Cell Expansion with Ronde-Cel Compared to CD19 CAR T-Cell Products After Infusion Better clinical response in CAR T-cell therapies has been shown to be associated with higher expansion Ronde-cel Expansion Ronde-cel vs CD19 CAR T-Cell Products Cmax 85,888 Median ddPCR Copies/µg DN
Slide 13: Ronde-Cel's Strong Product Memory Phenotype is Correlated with Higher Expansion
Ronde-Cel’s Strong Product Memory Phenotype is Correlated with Higher Expansion Patients with higher expression of memory-related genes have higher CAR T-cell peak expansion IL7R Set of 74 Genes Central Memory Marker Gene Memory Geneset p-value = 3.1e-05 p-value = 0.025 3e+05 3e+05 1e+05 1e+05 Cmax
Slide 14: Summary of Key Translational Findings
CD62L+ Enrichment of T Cells Achieves Robust Expansion, Memory Phenotype, and Sustained Function After Infusion in Patients with Large B-Cell Lymphoma Summary of Key Translational Findings Ronde-cel drug products have a high proportion of CD62L+ cells with a stronger memory-cell 1 phenotype compared
Slide 15: Ronde-Cel has a Higher Memory Phenotype One Month After Infusion Compared to Axi-Cel
Ronde-Cel has a Higher Memory Phenotype One Month After Infusion Compared to Axi-Cel Enhanced proportion of memory phenotype (GZMBloKRLG1lo) may improve CAR-T cell persistence and durability CAR T-Cell Infusion Study Description • Peripheral blood mononuclear cells were collected one month after tre
Slide 16: Higher Proportion of Memory Cells and Cytokine Expression One Month After Infusion
Ronde-Cel has a Higher Proportion of Memory Cells and Higher Gene Expression of Cytokines One Month After Infusion Compared to Axi-Cel Higher proportion of GZMBloKLRG1lo cells (TSCM, TCM, TEM) and higher IFNG and TNF expression Memory Cell Proportion (TSCM, TCM, TEM) Cytokine Gene Expression IFNG TN
Slide 17: Sustained Anti-Tumor Activity of Ronde-Cel's CD62L+ Enriched Cells Assessed After Infusion
Sustained Anti-Tumor Activity of Ronde-Cel’s CD62L+ Enriched Cells Were Assessed After Infusion Experimental method enabled by high numbers of CAR T-cells in circulation two months after infusion CAR T-Cell Infusion Study Description • Co-culture peripheral blood cells with tumor cell line One month
Slide 18: Summary of Key Translational Findings
CD62L+ Enrichment of T Cells Achieves Robust Expansion, Memory Phenotype, and Sustained Function After Infusion in Patients with Large B-Cell Lymphoma Summary of Key Translational Findings Ronde-cel drug products have a high proportion of CD62L+ cells with a stronger memory-cell 1 phenotype compared
Slide 19: Ronde-Cel Two Months After Infusion Proliferates, Kills, and Secretes Cytokines
Ronde-Cel Two Months After Infusion Proliferates, Kills, and Secretes Cytokines High memory phenotype and enhanced expansion of ronde-cel enable sustained functional capacity Proliferation Cytotoxicity Cytokine Secretion 100 1500 Ratio of Tumor Cells to Baseline Tumor cell alone Patient 1 Patient 2
Slide 20: Ronde-Cel from Two Months After Infusion Kills Tumor B-Cells in In Vitro Co-Culture
Ronde-Cel from Two Months After Infusion Kills Tumor B-Cells in In Vitro Co-Culture Pink cells = tumor cells; grey cells = patient peripheral blood mononuclear cells Ronde-cel demonstrates sustained tumor killing two months after infusion (72-hour timelapse video) 20 Tumor cell line used is Nalm6.
Slide 21: Summary of Key Translational Findings
CD62L+ Enrichment of T Cells Achieves Robust Expansion, Memory Phenotype, and Sustained Function After Infusion in Patients with Large B-Cell Lymphoma Summary of Key Translational Findings Ronde-cel drug products have a high proportion of CD62L+ cells with a stronger memory-cell 1 phenotype compared
Lyell Immunopharma — American Society of Hematology (ASH) 2025 on 6ix